This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Mueller, R. Search for Related Content PubMed PubMed Citation Articles by Mueller, R. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Blood and Blood Disorders Social Bookmarking                         What's this?

On the Therapy of Disturbances of Blood Fluidity

From Clinical Research, Hoechst AG, Werk Albert, Wiesbaden, West Germany

Physiology and pathophysiology of blood fluidity are reviewed focussing the clinical relevance of the different hyperviscosity syndroms with particular re spect to the microcirculation and thromboembolic complications. A new thera peutical approach is presented with pentoxifylline*, a drug which largely satisfies the complex requirements of a compound affecting most of the determi nants of disturbed blood fluidity. The presented data of the multifunctional pharmacological properties of pentoxifylline on blood components and vessel wall suggest this drug as indicated for the treatment of the disorders of blood fluidity linked with many diseases. Its antihemostasiological and antithrombotic potential also offers the facility for prevention of postoperative thrombotic events and in vessel surgery to avoid reocclusion.

Angiology, Vol. 36, No. 4, 226-234 (1985)
DOI: 10.1177/000331978503600405


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				N.S. Angelides, Ch. Angastiniotis, and N. Pavlides Effect of Pentoxifylline on Treatment of Lower Limb Ulcers in Patients with Thalassemia Major Vascular and Endovascular Surgery, May 1, 1994; 28(4): 275 - 281. [Abstract] [PDF]

				N.S. Angelides, Ch. Angastiniotis, and N. Pavlides Effect of Pentoxifylline on Treatment of Lower Limb Ulcers in Patients with Thalassemia Major Vascular and Endovascular Surgery, September 1, 1993; 27(7): 519 - 524. [Abstract] [PDF]

				A. Ramani, G.N. Kundaje, and M.N. Nayak Hemorheologic Approach in the Treatment of Diabetic Foot Ulcers Angiology, August 1, 1993; 44(8): 623 - 626. [Abstract] [PDF]

				N.S. Angelides, Ch. Angastiniotis, and N. Pavlides Effect of Pentoxifylline on Treatment of Lower Limb Ulcers in Patients with Thalassemia Major Angiology, July 1, 1992; 43(7): 549 - 554. [Abstract] [PDF]

				G. Rudofsky, K.F. Haussler, H.P. Kunkel, H. Schneider-May, F. Spengel, O. Symann, and H.-J. Werner Intravenous Treatment of Chronic Peripheral Occlusive Arterial Disease: A Double-Blind, Placebo-Controlled, Randomized, Multicenter Trial of Pentoxifylline Angiology, July 1, 1989; 40(7): 639 - 649. [Abstract] [PDF]

				E. Ott, E. Korner, and H. Lechner Hemorheologic Treatment of Cerebral Reversible Ischemic Episodes with Pentoxifylline A Prospective Study Angiology, June 1, 1988; 39(6): 520 - 525. [Abstract] [PDF]

				A. Radmilovic, Z. Boric, T. Naumovic, M. Stamenkovic, and P. Musikic Shunt Thrombosis Prevention in Hemodialysis Patients A Double-Blind, Randomized Study: Pentoxifylline vs Placebo Angiology, July 1, 1987; 38(7): 499 - 506. [Abstract] [PDF]

				R. H. Schroer Antithrombotic Potential of Pentoxifylline A Hemorheologically Active Drug Angiology, June 1, 1985; 36(6): 387 - 398. [Abstract] [PDF]